

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

BO

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>A61K 9/127, 47/44, B01J 13/02</b>	<b>A1</b>	<b>(11) International Publication Number:</b> WO 92/05771 <b>(43) International Publication Date:</b> 16 April 1992 (16.04.92)
<b>(21) International Application Number:</b> PCT/SE91/00639 <b>(22) International Filing Date:</b> 24 September 1991 (24.09.91) <b>(30) Priority data:</b> 9003100-6 28 September 1990 (28.09.90) SE <b>(71) Applicant (for all designated States except US):</b> KABI PHARMACIA AB [SE/SE]; S-751 82 Uppsala (SE). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> HERSLÖF, Bengt [SE/SE]; Matrosbacken 9, S-117 47 Stockholm (SE). NICK-LASSON, Martin [SE/SE]; Bränningestrandsvägen 72, S-151 39 Södertälje (SE). <b>(74) Agents:</b> TANNERFELDT, Agneta et al.; Kabi Pharmacia AB, S-112 87 Stockholm (SE).		<b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent), US.  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> LIPID FORMULATION SYSTEM  <b>(57) Abstract</b> <p>The invention relates to a lipid particle forming matrix, characterized by, that from a defined system of at least two lipid components chosen from classes of different polarity, in which at least one of the lipid components is bilayer forming, discrete lipid particles are formed spontaneously when interacting with aqueous systems. Preferably at least one of the lipid components is amphiphatic and polar and one is nonpolar. These discrete particles are formed spontaneously from the matrix without any chemical or physical treatment or initiation. The lipid particle forming matrix can contain bioactive materials, chosen from the group of drugs, herbicides, pesticides, fertilizers, food and cosmetic ingredients or additives. The invention also relates to a process for the production of the matrix, the use of the lipid particle forming matrix as a carrier system for bioactive materials and pharmaceutical composition such as oral, rectal, nasal, vaginal, ocular or parenteral vehicles, creams, ointments, capsules and tablets containing the said lipid particle forming matrix and a drug.</p>		

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU <sup>+</sup>	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE*	Germany	MC	Monaco	US	United States of America
DK	Denmark				

<sup>+</sup> Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

## LIPID FORMULATION SYSTEM

### INTRODUCTION

The present invention relates to lipid matrices which provide the release of bioactive agents through the formation of a type of liposomes *in vivo* when the matrices interact with water. The spherical lipid bilayers thus formed *in vivo*, hereinafter referred to as Biosomes (or lipid particle) and the lipid matrix, referred to as a Biosome Forming Matrix (BFM), should be separated from the well established concept of liposomes or liposome technology which are defined as the formation of lipid vesicles in an aqueous phase or in a freeze-dried form already prepared *in vitro* before administration. The invention also relates to the production and use of these lipid matrices (BFM).

### BACKGROUND

Parenteral depot systems are widely known to those skilled in the art and are well accepted concepts for long term delivery of drugs. These systems are based on biodegradable polymer systems or lipid formulations, e.g. oil solutions and oil suspensions. However, both systems show a serious disadvantage since, after the drug release process has terminated, the lipids or polymer carriers are still at the injection site for a long period of time and, for some systems such as implants, they may even have to be eliminated by surgery. Furthermore, the application of either oils or biodegradable polymers such as polylactic/polyglycolic acid show limited applications since each concept requires specific physicochemical properties of the bioactive material to be included into the systems, e.g. solubility or stability/compatibility.

Hence, parenteral therapy needs a delivery system for bioactive materials applicable for both highly polar as well as nonpolar bioactive materials for which the delivery system shows an intrinsic rate controlling mechanism for drug release, which can be varied over an extensive time frame. A characteristic for such delivery system should be that both the drug release and the biodegradation occur simultaneously.

Since parenteral administration of bioactive materials often needs to be carried out by physicians or nurses and the fact that many people find such therapy uncomfortable, a lot of effort is made on developing drug delivery

forms applicable for other routes of administration. Still, the most common route of administration is the enteral (oral, rectal) but during the past decade several attempts have been made to develop intranasal or transdermal delivery systems as alternatives to the parenteral route.

However, the adsorption through biological membranes is a very complex process due to the varying nature of the different membranes to be bypassed as well as the varying nature of the bioactive material used. Many enterally administered drugs also show a high biotransformation when absorbed from the gastrointestinal tract or show a restricted or erratic absorption capacity due to their physicochemical properties, molecular size or sensitivity to degradation processes in the gut, or due to some specific absorption mechanism in limited parts of the gastrointestinal tract. Also, bioactive material administered intranasally or dermally may show erratic and irregular absorption and many delivery formulations hence need the addition of absorption enhancers which in some cases have been shown to be detrimental to the nasal mucosa or the skin due to local side effects.

Due to this lack of regularity, the enteral/nasal/dermal therapy needs a delivery system which eliminates this variability and which is sufficiently flexible for incorporating a variety of bioactive materials, independent of their physicochemical properties, molecular size or source of origin, particularly for such bioactive materials which currently cannot be administered via the enteral route due to limited absorption capacity.

Several papers have been published demonstrating the influence of lipids on drug absorption. However, various results have been obtained showing an enhanced oral absorption either in man or animals, for example:

- griseofulvin in an oil-in-water emulsion (Bates and Sequeria, J. Pharm. Sci., 1975, 64, 793),
- cefoxitin in an oil-in-water emulsion (Palin et al., Int. J. Pharm., 1986, 33, 99),
- insulin in liposomes of phosphatidylcholine/cholesterol, as well as in water-in-oil microemulsion (Patel and Ryman, FEBS Letters, 1976, 62, 60; Cho and Flynn, Lancet, 1989, Dec. 23/30),
- cyclosporine in microemulsion (Tarr and Yalkowsky, Pharm. Res. 1989, 6, 40),

enhanced nasal absorption in rats of insulin in solution with lysophosphatidylcholine (Illum et al., Int. J. Pharm., 1989, 57, 49).

Decreased absorption was found for propranolol in coconut oil (Palin et al., J. Pharm. Pharmacol., 1989, 41, 579) or no effect at all for vitamin K incorporated into mixed micelles based upon glycolate and lecithin (Winn et al., J. Pharm. Pharmacol., 1989, 41, 257). Furthermore, Rowland and Woodley (Biochim. Biophys. Acta, 1980, 620, 400) have shown that many liposomal systems are quite unstable in the gastrointestinal tract and that drugs incorporated into liposomes gave the same absorption compared to free drug *per se*. It has recently been indicated in thermodynamic studies, that human insulin-DEAE-dextran complex entrapped in liposomes may present a more stable system than the uncomplexed and/or unentrapped human insulin. However, no evidence that this really works *in vivo* have been shown (Manosroi et al., Drug Dev. Ind. Pharm., 1990, 16, 837).

In some cases there is a therapeutic need to administer bioactive materials locally, such as in wounds after surgery or for the treatment of burns. In those cases, a need exists to deliver the bioactive material locally as well as for an extended period of time in a controllable manner since after surgery no further administration of the formulation is possible, and as in the case of burn injuries, pain may cause severe discomfort to the patient upon repeated administrations. Furthermore, local application to other regions in the body, such as in the vagina, with an extended drug delivery may show therapeutic advantages.

It is well known to those skilled in the art that bioactive materials can be entrapped into unique lipid/aqueous spherical structures defined as liposomes. A liposome is defined as a structure consisting of one or more concentric spheres of lipid bilayers separated by water or aqueous buffer compartments. Thus far, liposome formation and hence manufacturing, has been restricted to techniques where the said formation is carried out *in vitro*.

Numerous patents and scientific papers on liposomes have been published and the technical field of applying various lipid derivatives in combination with amphiphatic compounds such as phospholipids are well known to those skilled in the art. Liposomes can be prepared by different methods using solvents, reduced pressure, two-phase systems, freeze drying, sonication etc.

(Weiner et al., Drug Dev. Ind. Pharm. 1989, 15, 1523). The process technology assigned to these methods is highly complicated. Due to the specific demand in terms of the physicochemical properties of the drug molecule in order to form stable liposome structures, only a limited number of candidate drugs have been shown to be applicable in liposomes formed *in vitro*. The major application of liposomes have so far been restricted to parenteral delivery and for cosmetic skin care products even though attempts have been made for other routes of administration such as oral, nasal, pulmonary. The applications for parenteral use have been focused on intravenous administration and drug targeting and to some minor extent for extended or controlled release from a depot. Thus far, the applications of liposomes are restricted to the formation and incorporation of bioactive materials *in vitro*.

A composition for oral delivery of drugs has been disclosed in a patent by Yesair (WO 86/05694), comprising non-esterified fatty acids, monoglycerides with fatty acids having 14-18 carbon atoms, lysophosphatidylcholine in which the fatty acid component has 14-18 carbon atoms and a drug. None of these single-chained components are bilayer-forming which is a prerequisite for at least one of the lipid components in the present invention.

US Patent 4,610,868 discloses a way of producing liposomes where water-soluble compounds are incorporated. However, this patent deals with globular structures present from the beginning, in contrast to the present invention. The said invention also uses organic solvents in the process which is in contrast to the present invention where the Biosomes are formed spontaneously without any chemical or physical treatment or initiation.

Other documents disclosing the preparation of liposomes are EP 158 441, EP 260 241 and WO 87/07502. According to EP 158 441, in contrast to the present invention, at least one water-miscible liquid (e.g. glycerol, ethanol) and 5-40 % water should be added to at least one membrane lipid (e.g. phospholipids such as soy lecithin and egg yolk lecithin). EP 260 241 discloses a dry lipid-based solid material which forms or reconstitutes liposomes in the presence of water. This composition should be dehydrated, e.g. through lyophilization or spray-drying which should not destroy the liposome structure. The liposome structure is thus present from the beginning, in contrast to the present invention. WO 87/07502 discloses a pro-liposome formulation comprising of at least one volatile liquid propellant and at least

one lipid component. Also in this case discrete particles are formed by dehydration and thus the liposomes are present from the beginning.

The current well known liposome technology, where the systems are prepared *in vitro* before administration, suffers from the disadvantage that the systems are quite unstable and factors such as temperature or other constituents present in the formulation may dramatically change the nature of the liposomes by irreversibly damaging the bilayers. It is also well known (see Weiner above) that liposomes composed of crude egg yolk phosphatides are not physically stable *in vitro* at ambient temperatures for more than a few months which limits the application of these formulations in routine practice. By applying the matrix according to the invention the above mentioned stability problems can be avoided.

The above mentioned problems and needs can be met by using a delivery system as described in this application. The present invention, relating to Biosome formation *in vivo*, will show advantages as compared to already well known lipid drug delivery systems.

The present invention discloses a way to produce, use and/or utilize an entrapment or adsorption procedure for bioactive substances into unique lipid matrices. Such a combination may be used as a pharmaceutical formulation within human and veterinary medicine, in agriculture, or as cosmetic or food/nutritional formulations.

Figure 1 shows a microscope photo of the formulation according to Example 9. Figure 2 shows a microscope photo of the formulation according to Example 10.

#### DESCRIPTION OF THE INVENTION

According to the invention a lipid particle forming matrix is characterized by that from a system of at least two defined lipid components chosen from classes of different polarity, in which at least one of the lipid components is bilayer forming, discrete lipid particles are formed spontaneously when interacting with excess aqueous systems. A defined lipid component is a lipid whose chemical composition is known and controlled. In the system at least one of the lipid components is amphiphatic and polar and one is nonpolar.

The amphiphatic and polar component is preferably phosphatidylcholine and the nonpolar lipid is preferably chosen from the classes of mono-, di- and triglycerides or a mixture thereof. At room temperature the lipid particle forming matrix has a liquid or semi-solid consistency.

The amount of the polar lipid class components should be in the range of 5-80 % (w/w) of the lipid system, preferably in the range of 10-60 % (w/w).

The amount of the polar and amphiphatic lipid class components should be in the range of 5-80 % (w/w) of the lipid system, preferably in the range of 25-50 % (w/w).

Preferably the lipid particle forming matrix contains bioactive materials, which could be chosen from the groups of drugs, herbicides, pesticides, fertilizers, food and cosmetic ingredients or additives. The amount of bioactive material is below 70 % (w/w) of the matrix, preferably below 50 % (w/w).

In the lipid particle forming matrix the discrete particles are formed spontaneously from the matrix without any chemical or physical treatment or initiation.

When preparing the lipid particle forming matrix the amphiphatic and polar or the nonpolar lipid is mixed with the bioactive material *per se*, or in solution, and preferably the nonpolar lipid or lipids are admixed to the mixture of the bioactive material and the amphiphatic and polar lipid or lipids.

The lipid particle forming matrix could be used as a carrier system for bioactive materials and especially in pharmaceutical compositions such as oral, rectal, nasal, vaginal, ocular or parenteral vehicles, creams, ointments, capsules and tablets and they could be used for the manufacturing of a pharmaceutical composition for enteral, parenteral, nasal, intravaginal, ocular administration or administration locally on skin, wounds or mucous membranes.

The property 'bilayer forming' is a well-known physical parameter and can easily be established by suitable physicochemical methods (e.g. surface balance method). The establishment of the formed discrete lipid particles can be done by physical and/or chemical methods, such as microscopy using polarized light, or diffraction methods.



The present invention relates to bioactive materials to be entrapped in lipid matrices and will not be restricted to any particular class of bioactive material in terms of physicochemical properties, molecular size or the source of origin, i.e. synthetic, biotechnological materials, etc. The variation in the lipid composition provides the control mechanism by which Biosomes are formed and thereby to the rate of Biosome formation which will serve as a controlling factor for either immediate or sustained release of the entrapped or associated bioactive materials.

The matrix of the invention can only be defined in general terms as given in Claim 1. The difference between the matrix according to the invention and already known lipid systems, is the capability of spontaneous formation of the Biosomes in contact with excess aqueous media. Thus, by a) using well defined lipid components from at least two different lipid classes and by b) designing these lipid components into unique lipid matrices which form Biosomes *in vivo* when interacting with water, the system according to the invention can be obtained.

A bioactive material, within the scope of the present invention, is defined in its broadest sense, such as a biologically active substance having effect and/or is used within human and/or veterinary medicine, cosmetics as well as within agricultural areas (pesticides, herbicides and/or fertilizers). Also included are areas such as food.

Any type of bioactive agent can be applied. Hence, this invention is focused on the principle of lipid particle forming matrices which may contain a bioactive agent where said bioactive agent and hence the Biosome forming matrix design are based upon the physicochemical properties of the various matrix components.

For the person skilled in the art it is obvious that these substances are not by any means limited to the use within the areas mentioned above, the substances can be, and are used for other purposes or indications than the ones described above. Furthermore, in human and veterinary medicine a pharmacologically active substance, a salt, solvate, enantiomer, or a polymorph thereof may be used, including substances that are synthetic or biosynthetic in their origin. In agricultural areas substances that are used as herbicides or substances that act as stimulators on crop may be used. Also substances that

have an effect on various parasites (pesticides) are included. Within the food area the invention may be used to incorporate additives, such as vitamins, preservatives, spices or other taste-carriers in order to protect and/or release such substances in connection with consumption or storage of food.

The following definitions are used:

*lipids* - a general term for natural or synthetic compounds consisting of acyl carriers, such as glycerol, sphingosine, cholesterol, and others or derivatives thereof, to which one or more fatty acids are or could be linked. Also similar molecules that contains a substantial hydrocarbon portion may be included.

The lipids used for the Biosome Forming Matrices (BFM) can be classified into different lipid classes depending on their polarity, namely:

*nonpolar lipid classes* - these have no polar head groups. Examples of nonpolar constituents are hydrocarbons, or non-swelling amphiphiles, such as mono-, di- and triacylglycerols, cholesterol, fatty alcohols or cholesterol esters.

*polar lipid classes* - these have polar head groups and possess surface activity, such as phospholipids or glycolipids. Depending on their specific interactions with water they are further subdivided into the categories of swelling and soluble amphiphiles.

*amphiphatic or amphiphilic lipid classes* - such as phospholipids and glycolipids, being surface active.

*bilayer forming lipid classes* - amphiphatic lipids, such as PC (phosphatidylcholine), sphingomyelin, PI (phosphatidylinositol), with a molecular geometry that preferentially leads to bilayer structures in the presence of water.

The lipids used for the BFM consist of a mixture of lipid classes characterized by their different polarities. Polar lipids, such as phospholipids or glycolipids, and nonpolar lipids, such as mono-, di- and triglycerides, are the main constituents in the system but also sterols, such as cholesterol, fatty acids, fatty alcohols and esters thereof as well as other lipid classes may be utilized. This well defined mixture of lipids from different classes as defined above, should not be confused with commercial products such as soybean oil, maize oil or soy lecithin and egg lecithin. To get the well defined lipid classes the

commercial material, such as an oil or a lecithin, is fractionated and then the different lipid classes are admixed as explained in more detail in the examples below.

Furthermore, derivatives of lipids may also be used in combination with the above mentioned lipids. One example of this is polyethyleneglycol coupled to phosphatidylethanolamine, which has shown to prolong the circulation time of liposomes after injection in the blood stream. Another example of such a derivative is palmitoylcarnitine which acts as an absorption enhancer for bioactive substances in the gut.

In the preferred way of initiating the formation of the BFM, the bioactive substance is admixed to a selected lipid, followed by admixing of a lipid of a different polarity. This polar/nonpolar alteration may be continued for as many cycles as necessary in the specific case, involving a range of lipids with different polarities.

The preferred way of incorporation of a bioactive substance into the BFM is to admix the bioactive substance to amphiphilic lipids in order to create a homogeneous formulation, where the amount of amphiphilic lipids generally is in the total range of 5-80 % (w/w). Such an amphiphilic lipid should be capable of spontaneous bilayer formation. Examples thereof are amphiphilic and polar lipid classes, such as phosphatidylcholine, phosphatidylglycerol, phosphatidylinositol or phosphatidylserine or mixtures thereof.

In order to prevent or delay an immediate interaction of the amphiphile(s) with exogenous water, the BFM should also contain one or more nonpolar lipid class. Examples of such nonpolar lipids are mono-, di- or triglycerols, cholesterol or its esters.

Endogenous water, ethanol or other solvents may be present in small amounts (not enough for Biosome formation) in the BFM if the bioactive substance needs such a solvate to be incorporated.

The design of the BFM includes not only the proper selection and/or combination of lipid classes, tailor-made for the solubilization of each bioactive substance, but also the proper selection of the distribution of fatty acids, i.e. the acyl groups attached to the utilized lipid classes. Variation of the acyl groups

gives different physicochemical properties as will be seen in the examples below.

By varying the geometrical shape of the main bilayer forming lipid class, i.e. the effective head group area in relation to the steric conformation of the hydrocarbon tails, the rate by which the Biosomes are formed from the BFM in a given aqueous environment can be affected and controlled.

A second way of affecting and controlling the formation of Biosomes is by varying the structure, thus the fluidity, of the hydrocarbon chains in the nonpolar part of the BFM. This will affect the rate of interaction of the endogenous amphiphatic lipids and the exogenous aqueous medium.

Thus, a careful selection of lipid constituents for a specific BFM will be required in order to a) incorporate the bioactive compound *in vitro* and to b) release the bioactive component by Biosome formation *in vivo*. This involves the selection of lipid classes as well as the distribution of the fatty acid residues and therefore requires access to analytically pure and well-characterized lipids. The examples below will further illustrate the variation of the matrices by selection of lipids and combinations thereof without limiting the scope of invention.

Thus, the invention relates particularly to the design and behaviour of the BFM which is a new concept for drug delivery of bioactive materials. The invention does not restrict the application of the BFM to any specific route of administration since the BFM will show potential applications for a variety of drug delivery forms such as absorption enhancement of oral, rectal, nasal, dermal formulations or controlled delivery via the parenteral route or locally, e.g. in the vagina or in wounds.

After the formation of the Biosomes *in vivo*, by means of a controllable rate, drug molecules entrapped into, or associated to the BFM are rapidly liberated once the Biosomes appear in the blood circulation in order for the drug to be able to act pharmacologically. This assumption is supported by the fact that liposomal structures are known to interact rapidly with plasma proteins such as albumin, transferrin and macroglobulins, but are also hydrolyzed *in vivo* by specific phospholipases (Wiener et al., Drug Dev. Ind. Pharm., 1989, 15,

1523). Thus, the use of mortar compounds may be omitted according to the present invention.

According to the present invention, it is possible to incorporate both highly polar as well as nonpolar bioactive materials, in a flexible manner, into a lipid matrix structure by means of a combination of nonpolar lipids and amphiphatic compounds and that these drug containing BFM's form Biosomes, when the BFM's interact with water, thus generating a drug delivery system suitable for either an enhanced or controlled extravascular absorption or a controlled parenteral drug release combined with a biodegradation.

The present invention provides an improved and flexible drug delivery system applicable for various classes of bioactive materials. *In vitro* release experiments of vitamin B12 (cyanocobolamine) have shown that it is possible to obtain BFM's with different Biosome forming rates as a function of the BFM composition. Furthermore, parenteral drug delivery with controlled release has been found even for highly water-soluble bioactive material such as fragmented heparin (Fragmin®) using the present invention. Such a combination of a highly hydrophilic bioactive substance with a hydrophobic carrier has hitherto not yet been shown. To those skilled in the art this new and unique property of the present lipid drug delivery carrier (i.e. BFM) must be regarded as highly unpredictable. The results which confirm this are shown in Examples 9, 10 and 15. Also, it has been shown to be possible to incorporate a synthetic low molecular weight substance, i.e. buspirone (cf. Example 22) as well as a high molecular weight compound, i.e. coenzyme Q10 (cf. Example 23).

By incorporating bioactive materials according to the lipid matrix principle in this invention, referred to as Biosome Forming Matrices, the following advantages are obtained compared to conventional pharmaceutical dosage forms, or delivery systems:

- a drug delivery system consisting of a lipid matrix and a bioactive material which can be designed in a flexible manner showing a unique capacity for incorporation of either polar or nonpolar bioactive materials showing a wide range of molecular weights without changing the chemical structure and hence the biological activity of the materials.

- a drug delivery system consisting of BFM and a bioactive material which forms Biosomes *in vivo* and for which the rate of Biosome formation can be altered by unique combinations of nonpolar and amphiphatic lipids derivatives.
- a drug delivery system consisting of a lipid matrix and a bioactive material which can be used for multipurpose applications such as extravascular absorption enhancement, parenteral controlled drug delivery or local extended drug delivery for which each specific purpose can be achieved by unique lipid combinations in a flexible manner.
- a drug delivery system consisting of a lipid matrix and bioactive material which is thermodynamically stable.
- a drug delivery system in which the drug and the carrier simultaneously are degraded.
- a drug delivery system which gives a possibility to improve the oral administration of high molecular weight compounds such as proteins, peptides, polysaccharides, etc.

This invention relates solely to the concept and design of the novel lipid matrices, the Biosome Forming Matrices, which show a unique formation of Biosomes *in vivo* after administration, and in which any suitable bioactive material can be incorporated, if needed for any particular reason, such as for improved bioavailability or for extended/controlled release purposes.

Various modifications and equivalents will be apparent to the one skilled in the art and may be used in the compounds, compositions and methods of the present invention without departing from the spirit or scope thereof, and it is therefore to be understood that the invention is not to be limited to the specific examples and embodiments herein.

**EXAMPLES****EXAMPLE 1**

1.25 g phospholipid from soybean (I) is added to 1.25 g of a glyceride mixture (II) and gently stirred for 12 h at 60 °C. 2.50 g of a triglyceride (III) is then added and the total mixture is stirred for 1 h at 60 °C.

<b><u>Lipid class composition (g)</u></b>	<b>I</b>	<b>II</b>	<b>III</b>	<b><i>Fatty acid composition of triacylglycerol (wt%)</i></b>	
Phosphatidylcholine	0.50				
Phosphatidylethanolamine	0.40				
Phosphatidylinositol	0.23				
Nonpolar lipids	0.12				
Monoacylglycerol		0.63			
Diacylglycerol		0.63			
Triacylglycerol			2.50		
				8:0 caprylate	58.5
				10:0 caprate	40.5
				12:0 laurate	0.6
				minors	0.4
<b>Total</b>	<b>1.25</b>	<b>1.25</b>	<b>2.50</b>	<b>Total</b>	<b>100</b>

**EXAMPLE 2**

1.25 g phospholipid from soybean (I) is added to 1.25 g of a glyceride mixture (II) and gently stirred for 12 h at 60 °C. 2.50 g of a triglyceride (III) is then added and the total mixture is stirred for 1 h at 60 °C.

<b><u>Lipid class composition (g)</u></b>	<b>I</b>	<b>II</b>	<b>III</b>	<b><i>Fatty acid composition of triacylglycerol (wt%)</i></b>	
Phosphatidylcholine	0.40				
Phosphatidylethanolamine	0.35				
Phosphatidylinositol	0.18				
Phosphatidic acid	0.07				
Nonpolar lipids	0.25				
Monoacylglycerol		0.63			
Diacylglycerol		0.63			
Triacylglycerol			2.50		
				8:0 caprylate	58.5
				10:0 caprate	40.5
				12:0 laurate	0.6
				minors	0.4
<b>Total</b>	<b>1.25</b>	<b>1.25</b>	<b>2.50</b>	<b>Total</b>	<b>100</b>

**EXAMPLE 3**

1.25 g phospholipids from soybean (I) is added to 1.25 g of a glyceride mixture (II) and gently stirred for 12 h at 60 °C. 2.50 g of a triglyceride (III) is then added and the total mixture was stirred for 1 h at 60 °C.

<u>Lipid class composition (g)</u>	I	II	III	<i>Fatty acid composition of triacylglycerol (wt%)</i>	
Phosphatidylcholine	0.50				
Phosphatidylethanolamine	0.40				
Phosphatidylinositol	0.23				
Nonpolar lipids	0.12				
Monoacylglycerol		0.63			
Diacylglycerol		0.63			
Triacylglycerol			2.50		
				16:0 palmitate	10.0
				18:0 stearate	2.8
				18:1 oleate	20.6
				18:2 linoleate	58.9
				18:3 linolenate	6.7
				minors	1.0
Total	1.25	1.25	2.50	Total	100

**EXAMPLE 4**

1.25 g phospholipid from soybean (I) is added to 1.25 g of a glyceride mixture (II) and gently stirred for 12 h at 60 °C. 2.50 g of a triglyceride (III) is then added and the total mixture was stirred for 1 h at 60 °C.

<u>Lipid class composition (g)</u>	I	II	III	<i>Fatty acid composition of triacylglycerol (wt%)</i>	
Phosphatidylcholine	0.40				
Phosphatidylethanolamine	0.35				
Phosphatidylinositol	0.18				
Phosphatidic acid	0.07				
Nonpolar lipids	0.25				
Monoacylglycerol		0.63			
Diacylglycerol		0.63			
Triacylglycerol			2.50		
				16:0 palmitate	10.0
				18:0 stearate	2.8
				18:1 oleate	20.6
				18:2 linoleate	58.9
				18:3 linolenate	6.7
				minors	1.0
Total	1.25	1.25	2.50	Total	100



**EXAMPLE 5**

1.25 g phospholipid from soybean (I) is added to 1.25 g of a glyceride mixture (II) and gently stirred for 12 h at 60 °C.

<u>Lipid class composition (g)</u>	I	II
Phosphatidylcholine	0.40	
Phosphatidylethanolamine	0.35	
Phosphatidylinositol	0.18	
Phosphatidic acid	0.07	
Nonpolar lipids	0.25	
Monoacylglycerol		0.63
Diacylglycerol		0.63
Triacylglycerol		
Total	1.25	1.25

**EXAMPLE 6**

1.25 g phospholipid from soybean (I) is added to 1.25 g of a glyceride mixture (II) and 0.16 g ethanol. The total mixture is gently stirred for 6 h at 60 °C. 0.16 g of a triglyceride (III) is added and the total mixture is stirred for another hour at the elevated temperature.

<u>Lipid class composition (g)</u>	I	II	III
Phosphatidylcholine	0.40		
Phosphatidylethanolamine	0.35		
Phosphatidylinositol	0.18		
Phosphatidic acid	0.07		
Nonpolar lipids	0.25		
Monoacylglycerol		0.63	
Diacylglycerol		0.63	
Triacylglycerol			0.16
Total	1.25	1.25	0.16

**EXAMPLE 7**

15 mg cyanocobalamin (B12) is added to 1.25 g of a glyceride mixture (II) and gently stirred for 3 h at 60 °C. 1.25 g phosphatidylcholine from soybean (I) is added and the stirring continues for 6 h at 60 °C. 2.50 g of a triglyceride (III) is added and the total mixture is stirred for another hour at the elevated temperature.

<u>Lipid class composition (g)</u>	I	II	III	<i>Fatty acid composition of triacylglycerol (wt%)</i>	
Phosphatidylcholine	1.25				
Monoacylglycerol		0.63			
Diacylglycerol		0.63			
Triacylglycerol			2.50		
				8:0 caprylate	58.5
				10:0 caprate	40.5
				12:0 laurate	0.6
				minors	0.4
Total	1.25	1.25	2.50	Total	100

**EXAMPLE 8**

15 mg cyanocobalamin (B12) is added to 1.25 g of a glyceride mixture (II) and gently stirred for 3 h at 60 °C. 1.25 g phosphatidylcholine from soybean (I) is added and the stirring continues for 6 h at 60 °C. 2.50 g of a triglyceride (III) is added and the total mixture is stirred for another hour at the elevated temperature.

<u>Lipid class composition (g)</u>	I	II	III	<i>Fatty acid composition of triacylglycerol (wt%)</i>	
Phosphatidylcholine	1.25				
Monoacylglycerol		0.63			
Diacylglycerol		0.63			
Triacylglycerol			2.50		
				16:0 palmitate	10.0
				18:0 stearate	2.8
				18:1 oleate	20.6
				18:2 linoleate	58.9
				18:3 linolenate	6.7
				minors	1.0
Total	1.25	1.25	2.50	Total	100

Below in Table I, viscosity, melting temperature and melting enthalpy have been measured for the compositions according to Examples 1-8.

Table I

Example	Viscosity (mPa s)	T <sub>m</sub> (°C)	ΔH (J/g)
1	167	—	—
2	104	-37.9 - 3.5	5.9 50.3
3	199	-72.1 -23.1	0.7 41.9
4	104	-72.1 -22.2	0.7 42.0
5	2100	-17.2	18.7
6	—	-26.1 + 6.4	36.5 14.4
7	133		
8	900		

Viscosity measured on a Bohlin VOR rheometer at 25 °C. T<sub>m</sub> (phase transition temperature) and ΔH (enthalpy change at transition) obtained by means of differential scanning calorimetry.

As can be seen in Table I, various physicochemical properties can be obtained for the BMF's as a function of the lipid combinations used as well as the fatty acid compositions. This will enable the manufacturing of BMF's showing a wide variety of physical properties.

**EXAMPLE 9**

30 mg cyanocobalamin (B12) is added to 2.50 g of a monoglyceride (II) and the mixture is gently stirred for 3 h at 60 °C. 2.50 g phosphatidylcholine from soybean (I) is added and the stirring continues for 6 h at 60 °C. 5.00 g of a triglyceride (III) is added and the total mixture is stirred for another hour at the elevated temperature.

<u>Lipid class composition (g)</u>	I	II	III	<i>Fatty acid composition of triacylglycerol (wt%)</i>	
Phosphatidylcholine	2.50				
Monoacylglycerol		2.50			
Triacylglycerol			5.00		
				8:0 caprylate	58.5
				10:0 caprate	40.5
				12:0 laurate	0.6
				minors	0.4
Total	2.50	2.50	5.00	Total	100

**EXAMPLE 10**

30 mg cyanocobalamin (B12) is added to 2.50 g of a monoglyceride (II) and the mixture is gently stirred for 3 h at 60 °C. 2.50 g phosphatidylcholine from soybean (I) is added and the stirring continues for 6 h at 60 °C. 5.00 g of a triglyceride (III) is added and the total mixture is stirred for another hour at the elevated temperature.

<u>Lipid class composition (g)</u>	I	II	III	<i>Fatty acid composition of triacylglycerol (wt%)</i>	
Phosphatidylcholine	2.50				
Monoacylglycerol		2.50			
Triacylglycerol			5.00		
				16:0 palmitate	10.0
				18:0 stearate	2.8
				18:1 oleate	20.6
				18:2 linoleate	58.9
				18:3 linolenate	6.7
				minors	1.0
Total	2.50	2.50	5.00	Total	100

Figure 1 shows a microscope photo of the formulation according to Example 9, 4 min after the addition of external water (magnification = 60x). It is apparent from the figure that lipid vesicles, denoted here as Biosomes, are formed from the Biosome Forming Matrix at the interface between aqueous and lipid phase

and that the process seems to occur by means of a spontaneous 'budding' mechanism which takes place immediately after contact with external water.

Figure 2 shows a microscope photo of the formulation according to Example 10, 10 s after the addition of external water (magnification = 60x). As can be seen, worm-like textures are formed in the lipid phase, i.e. the Biosome Forming Matrix, which moves towards the interface between water and lipid. Then at the water-lipid interface, these textures are rapidly transformed by a 'budding' process into spherical lipid vesicles, denoted as Biosomes in this invention.

The *in vitro* release of vitamin B12 from the BFM's in Examples 9 and 10 was tested. The BMF formulations were added to water at 20 °C and then shaken gently for 3 min before measuring the B12 concentration in the aqueous phase. The formulations were allowed to stand for 120 min followed by a repeated analysis. In order to obtain a clear aqueous phase, centrifugation was performed for 30 min at 45,000 rpm before concentration measurements. The results are shown in Table II.

Table II

Time (min)	Release	
	Example 9	Example 10
3	85 %	76 %
120	85 %	84 %

As can be seen, a very rapid and spontaneous release of vitamin B12 was obtained from the two BFM formulations. Also, depending on the lipid composition, different release properties were obtained. Only small changes in the fatty acid composition gave different release properties. The lipid particles according to the experiment given in Table II above, i.e. Biosomes formed from Examples 9 and 10, were subjected to size analysis using a Malvern equipment. The results thus obtained are shown in Table III.

Table III

Example No.	Time (min)	Size		
9	3	26 % <1 $\mu$ m	>1 $\mu$ m	66 % <2 $\mu$ m
	120	41 % <1 $\mu$ m	>1 $\mu$ m	46 % <2 $\mu$ m
10	3	0 % <1 $\mu$ m	>1 $\mu$ m	96 % <10 $\mu$ m
	120	44 % <1 $\mu$ m	>1 $\mu$ m	52 % <2 $\mu$ m

Initially, smaller Biosomes are spontaneously formed for Example 9 compared to Example 10 as evident from Table III. Furthermore, for the smaller Biosome forming matrices a more rapid drug release can be seen, cf. Table II. Another interesting phenomenon can be seen in Table III in terms of the time for the formation of smaller Biosomes. A longer lag time for this process was found for Example 10 compared to Example 9 which demonstrated the possibility of controlling this process by means of lipid composition in the BFM's.

**EXAMPLE 11**

2.50 g phosphatidylcholine from soybean (I) and 7.50 g of a monoglyceride (II) are gently stirred for 6 h at 60 °C. 1.25 g water is added and the stirring continues for another hour at the elevated temperature.

<u>Lipid class composition (g)</u>	I	II
Phosphatidylcholine	2.50	
Monoacylglycerol		7.50
Total	2.50	7.50

**EXAMPLE 12**

2.50 g phosphatidylcholine from soybean (I) and 7.50 g of a monoglyceride (II) are gently stirred for 6 h at 60 °C. 1.25 g Fragmin® solution (120 mg/g water) is added and the stirring continues for another hour at the elevated temperature.

<u>Lipid class composition (g)</u>	I	II
Phosphatidylcholine	2.50	
Monoacylglycerol		7.50
Total	2.50	7.50

**EXAMPLE 13**

2.50 g phosphatidylcholine from soybean (I) and 7.50 g of a monoglyceride (II) are gently stirred at 60 °C for 6 h. 0.625 g Fragmin® solution (120 mg/g water) is added and the stirring continues for another hour at the elevated temperature.

<u>Lipid class composition (g)</u>	I	II	<i>Fatty acid composition of monoacylglycerol (wt%)</i>	
Phosphatidylcholine	2.50			
Monoacylglycerol		7.50	8:0 caprylate	79.6
			10:0 caprate	19.8
			12:0 laurate	0.2
			minors	0.4
Total	2.50	7.50	Total	100

**EXAMPLE 14**

2.50 g phosphatidylcholine from soybean (I) and 7.50 g of a monoglyceride (II) are gently stirred at 60 °C for 6 h. 1.25 g Fragmin® solution (120 mg/g water) is added and the stirring continues for another hour at the elevated temperature.

<u>Lipid class composition (g)</u>	I	II	<i>Fatty acid composition of monoacylglycerol (wt%)</i>	
Phosphatidylcholine	2.50			
Monoacylglycerol		7.50	8:0 caprylate	78.4
			10:0 caprate	21.2
			12:0 laurate	0.2
			minors	0.2
Total	2.50	7.50	Total	100

**EXAMPLE 15**

2.50 g phosphatidylcholine from soybean (I) and 7.50 g of a monoglyceride (II) are gently stirred at 60 °C for 6 h. 0.625 g Fragmin<sup>®</sup> solution (120 mg/g water) is added and the stirring continues for another hour at the elevated temperature.

<u>Lipid class composition (g)</u>	I	II	<i>Fatty acid composition of monoacylglycerol (wt%)</i>	
Phosphatidylcholine	2.50			
Monoacylglycerol		7.50		
			8:0 caprylate	78.4
			10:0 caprate	21.2
			12:0 laurate	0.2
			minors	0.2
Total	2.50	7.50	Total	100

The size distribution of the Biosomes formed in water at 37 °C was determined for Example 15 using a Malvern equipment. The BFM formulation was shaken gently in water for 17 h followed by centrifugation in order to separate the lipid phase from the aqueous phase. The result is shown in Table IV.

Table IV

Size	%
<1 µm	36
>1 µm, <2 µm	60

Example 15 was also administered in a rabbit by subcutaneous injection. Blood samples were collected and the plasma concentration of Fragmin<sup>®</sup> was analyzed as a function of time. The results are shown in Table V.



Table V

Time (h)	Fragmin® plasma concentration (IU/ml)
0	0
1.0	0
2.0	0
2.5	0.051
3.0	0.100
3.5	0.110
4.0	0.127
4.5	0.130
5.0	0.122
5.5	0.126
6.0	0.133
7.0	0.126

As can be seen in Table V, a constant and extended release of Fragmin® was obtained *in vivo*. It seems as if it is now possible to deliver *in vivo* a highly water-soluble high molecular weight compound at a constant rate by means of the present invention.

Examples 16-23 show various formulations based on the present invention demonstrating the flexibility of said invention. The examples show that it is possible to incorporate both highly complex molecules such as vitamin B12 as well as low molecular weight compound, e.g. buspirone and high molecular weight molecules, e.g. fragmented heparin (Fragmin®) where each bioactive compound possesses different physicochemical properties.

**EXAMPLE 16**

150 mg cyanocobalamin (B12) is added to 12.50 g of a monoglyceride (II) and the mixture is gently stirred at 60 °C for 3 h. 12.50 g phosphatidylcholine from soybean (I) is added and the stirring continues for 6 h at 60 °C. 25.00 g of a triglyceride (III) is added and the total mixture is stirred for another hour at the elevated temperature.

<u>Lipid class composition (g)</u>	I	II	III	<i>Fatty acid composition of triacylglycerol (wt%)</i>	
Phosphatidylcholine	12.50				
Monoacylglycerol		12.50			
Triacylglycerol			25.00		
				8:0 caprylate	58.5
				10:0 caprate	40.5
				12:0 laurate	0.6
				minors	0.4
Total	12.50	12.50	25.00	Total	100

**EXAMPLE 17**

150 mg cyanocobalamin (B12) is added to 12.50 g of a monoglyceride (II) and the mixture is gently stirred at 60 °C for 3 h. 12.50 g phosphatidylcholine from soybean (I) is added and the stirring continues for 6 h at 60 °C. 25.00 g of a triglyceride (III) is added and the total mixture is stirred for another hour at the elevated temperature.

<u>Lipid class composition (g)</u>	I	II	III	<i>Fatty acid composition of triacylglycerol (wt%)</i>	
Phosphatidylcholine	12.50				
Monoacylglycerol		12.50			
Triacylglycerol			25.00		
				16:0 palmitate	10.0
				18:0 stearate	2.8
				18:1 oleate	20.6
				18:2 linoleate	58.9
				18:3 linolenate	6.7
				minors	1.0
Total	12.50	12.50	25.00	Total	100

**EXAMPLE 18**

150 mg cyanocobalamin (B12) is added to 33.30 g of a monoglyceride (II) and the mixture is gently stirred at 60 °C for 3 h. 11.10 g phosphatidylcholine from soybean (I) is added and the stirring continues for 6 h at 60 °C. 5.60 g of water is added and the total mixture is stirred for another hour at the elevated temperature.

<u>Lipid class composition (g)</u>	I	II
Phosphatidylcholine	11.10	
Monoacylglycerol		33.30
Triacylglycerol		
Total	11.10	33.30

**EXAMPLE 19**

15 mg cyanohydroxycobalamin acetate is added to 1.25 g of a glyceride mixture (II) and gently stirred at 60 °C for 3 h. 1.25 g phosphatidylcholine from soybean (I) is added and the stirring continues for 6 h at 60 °C. 2.50 g of a triglyceride (III) is added and the total mixture is stirred for another hour at the elevated temperature.

<u>Lipid class composition (g)</u>	I	II	III	<i>Fatty acid composition of triacylglycerol (wt%)</i>	
Phosphatidylcholine	1.25				
Monoacylglycerol		0.63			
Diacylglycerol		0.63			
Triacylglycerol			2.50		
				8:0 caprylate	58.5
				10:0 caprate	40.5
				12:0 laurate	0.6
				minors	0.4
Total	1.25	1.25	2.50	Total	100

**EXAMPLE 20**

15 mg cyanohydroxycobalamin acetate is added to 1.25 g of a glyceride mixture (II) and gently stirred at 60 °C for 3 h. 1.25 g phosphatidylcholine from soybean (I) is added and the stirring continues for 6 h at 60 °C. 2.50 g of a triglyceride (III) is added and the total mixture is stirred for another hour at the elevated temperature.

<u>Lipid class composition (g)</u>	I	II	III	<i>Fatty acid composition of triacylglycerol (wt%)</i>	
Phosphatidylcholine	1.25			16:0 palmitate	10.0
Monoacylglycerol		0.63		18:0 stearate	2.8
Diacylglycerol		0.63		18:1 oleate	20.6
Triacylglycerol			2.50	18:2 linoleate	58.9
				18:3 linolenate	6.7
				minors	1.0
Total	1.25	1.25	2.50	Total	100

**EXAMPLE 21**

2.50 g phosphatidylcholine from soybean (I) and 7.50 g of a monoglyceride (II) are gently stirred for 6 h at 60 °C. 2.0 ml Fragmin® solution (334 mg/g water) is added and the stirring continues for another hour at the elevated temperature.

<u>Lipid class composition (g)</u>	I	II
Phosphatidylcholine	2.50	
Monoacylglycerol		7.50
Total	2.50	7.50

**EXAMPLE 22**

10 mg buspirone hydrochloride is added to 50 mg of a monoglyceride (II) and the mixture is gently stirred for 1 h at 60 °C. 200 mg of a diglyceride (III) and 250 mg phosphatidylcholine from soybean (I) is added and the stirring continues for 3 h at 60 °C. 500 mg of a triglyceride (IV) is added and the total mixture is stirred for another 10 min at the elevated temperature.

<u>Lipid class composition (mg)</u>	I	II	III	IV	<i>Fatty acid composition of triacylglycerol (wt%)</i>	
Phosphatidylcholine	250				8:0 caprylate	58.5
Monoacylglycerol		50			10:0 caprate	40.5
Diacylglycerol			200		12:0 laurate	0.6
Triacylglycerol				500	minors	0.4
Total	250	50	200	500	Total	100

**EXAMPLE 23**

20 mg coenzyme Q10 is added to 200 mg of a diglyceride (II) and 250 mg phosphatidylcholine from soybean (I) and the mixture is gently stirred for 6 h at 60 °C. 500 mg of a triglyceride (III) is added and the total mixture is stirred for another hour at the elevated temperature.

<u>Lipid class composition (mg)</u>	I	II	III	<i>Fatty acid composition of triacylglycerol (wt%)</i>	
Phosphatidylcholine	250			8:0 caprylate	58.5
Diacylglycerol		200		10:0 caprate	40.5
Triacylglycerol			500	12:0 laurate	0.6
				minors	0.4
Total	250	200	500	Total	100

## CLAIMS

1

Lipid particle forming matrix, characterized by, that from a defined system of at least two lipid components chosen from classes of different polarity, in which at least one of the lipid component is bilayer forming, discrete lipid particles are formed spontaneously when interacting with excess aqueous medium.

2

Lipid particle forming matrix according to Claim 1, characterized by that in the system at least one of the lipid components is amphiphatic and polar and one is nonpolar.

3

Lipid particle forming matrix according to any of Claims 1 or 2, characterized by that the nonpolar lipid is chosen from the class of mono-, di- and triglycerides or a mixture thereof.

4

Lipid particle forming matrix according to any of Claims 1-3, characterized by that the nonpolar lipid contains a triglyceride with essentially a mixture of 8:0 caprylate and 10:0 caprate.

5

Lipid particle forming matrix according to any of Claims 1-3, characterized by that the nonpolar lipid contains a triglyceride with essentially a mixture of 18:2 linoleate, 18:1 oleate and 16:0 palmitate.

6

Lipid particle forming matrix according to any of Claims 1-3, characterized by that the nonpolar lipid contains a monoglyceride with essentially a mixture of 8:0 caprylate and 10:0 caprate.

7

Lipid particle forming matrix according to Claim 2, characterized by that the amounts of the amphiphatic and polar lipid components are in the range of 5-80 % (w/w) of the lipid system, preferably in the range of 10-60 % (w/w).

8

Lipid particle forming matrix according to Claim 7, characterized by that the amphiphatic and polar lipid components are bilayer forming and in an amount of 25-50 % (w/w) of the lipid system.

9

Lipid particle forming matrix according to any of Claims 2 and 7-8, characterized by that the amphiphatic and polar lipid components are chosen from phosphatidylcholine, and other phospholipids.

10

Lipid particle forming matrix according to any of Claims 2 and 8-9, characterized by that the amphiphatic and polar lipid components is phosphatidylcholine in an amount of 50 % (w/w).

11

Lipid particle forming matrix according to any of the Claims 1-10, characterized by that the lipid particle forming matrix contains bioactive materials.

12

Lipid particle forming matrix according to Claim 11, characterized by that the bioactive material is chosen from the groups of drugs, herbicides, pesticides, fertilizers, food and cosmetic ingredients or additives.

13

Lipid particle forming matrix according to Claims 11 and 12, characterized by that the amount of bioactive material is below 70% (w/w) of the matrix, preferably below 50% (w/w).

14

Lipid particle forming matrix according to Claims 1-10, characterized by that discrete particles are formed spontaneously from the matrix without any chemical or physical treatment or initiation.

15

Process for the production of a lipid particle forming matrix according to any of the Claims 11-13, characterized by that the amphiphatic and polar or the nonpolar lipid is mixed with the bioactive material *per se* or in solution.

16

Process according to Claim 15, characterized by a first admixing of nonpolar lipid or lipids with the bioactive material and thereafter admixing with the amphiphatic and polar lipid or lipids.

17

Use of the lipid particle forming matrix according to any of Claims 1-10, as a carrier system for bioactive materials.

18

Pharmaceutical composition such as oral, rectal, nasal, vaginal, ocular or parenteral vehicles, creams, ointments, capsules and tablets containing the said lipid particle forming matrix according to any of Claims 11-13 and a carrier.

19

Use of the lipid particle forming matrix according to any of Claims 11-13, for the manufacturing of a pharmaceutical composition for enteral, parenteral, nasal, intravaginal, ocular administration or administration locally on skin, wounds or mucous membranes.






Figure 1







Figure 2

# INTERNATIONAL SEARCH REPORT

International Application No PCT/SE 91/00639

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>6</sup> According to International Patent Classification (IPC) or to both National Classification and IPC IPC5: A 61 K 9/127, 47/44, B 01 J 13/02																	
<b>II. FIELDS SEARCHED</b> <div style="text-align: center;">Minimum Documentation Searched<sup>7</sup></div> <table style="width: 100%; border: none;"> <tr> <td style="width: 30%; border: none;">Classification System</td> <td style="border: none;">Classification Symbols</td> </tr> <tr> <td style="border: 1px solid black; padding: 5px;">IPC5</td> <td style="border: 1px solid black; padding: 5px;">A 61 K; B 01 J</td> </tr> </table>			Classification System	Classification Symbols	IPC5	A 61 K; B 01 J											
Classification System	Classification Symbols																
IPC5	A 61 K; B 01 J																
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched <sup>8</sup>  SE,DK,FI,NO classes as above																	
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%;">Category<sup>*</sup></th> <th style="width: 60%;">Citation of Document,<sup>11</sup> with indication, where appropriate, of the relevant passages<sup>12</sup></th> <th style="width: 30%;">Relevant to Claim No.<sup>13</sup></th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top;">X</td> <td>EP, A, 0158441 (PHARES PHARMACEUTICAL RESEARCH N.V.) 16 October 1985, see page 5, line 1 - page 6, line 16; page 8, line 5 - page 9, line 18; page 12, line 18 - line 34 --</td> <td style="text-align: center; vertical-align: top;">1-3,9, 11-19</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">X</td> <td>EP, A, 0260241 (AKTIEBOLAGET DRACO) 16 March 1988, see page 3, line 20 - line 63 --</td> <td style="text-align: center; vertical-align: top;">1-2,9, 11-19</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">X</td> <td>WO, A1, 8707502 (PHARES PHARMACEUTICAL RESEARCH N.V.) 17 December 1987, see pages 1-3, example 3 and claims --</td> <td style="text-align: center; vertical-align: top;">1-3,9, 11-19</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">A</td> <td>EP, A, 0084169 (AUSONIA FARMACEUTICI SRI) 27 July 1983, see the whole document --</td> <td style="text-align: center; vertical-align: top;">1-19</td> </tr> </tbody> </table>			Category <sup>*</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>	X	EP, A, 0158441 (PHARES PHARMACEUTICAL RESEARCH N.V.) 16 October 1985, see page 5, line 1 - page 6, line 16; page 8, line 5 - page 9, line 18; page 12, line 18 - line 34 --	1-3,9, 11-19	X	EP, A, 0260241 (AKTIEBOLAGET DRACO) 16 March 1988, see page 3, line 20 - line 63 --	1-2,9, 11-19	X	WO, A1, 8707502 (PHARES PHARMACEUTICAL RESEARCH N.V.) 17 December 1987, see pages 1-3, example 3 and claims --	1-3,9, 11-19	A	EP, A, 0084169 (AUSONIA FARMACEUTICI SRI) 27 July 1983, see the whole document --	1-19
Category <sup>*</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>															
X	EP, A, 0158441 (PHARES PHARMACEUTICAL RESEARCH N.V.) 16 October 1985, see page 5, line 1 - page 6, line 16; page 8, line 5 - page 9, line 18; page 12, line 18 - line 34 --	1-3,9, 11-19															
X	EP, A, 0260241 (AKTIEBOLAGET DRACO) 16 March 1988, see page 3, line 20 - line 63 --	1-2,9, 11-19															
X	WO, A1, 8707502 (PHARES PHARMACEUTICAL RESEARCH N.V.) 17 December 1987, see pages 1-3, example 3 and claims --	1-3,9, 11-19															
A	EP, A, 0084169 (AUSONIA FARMACEUTICI SRI) 27 July 1983, see the whole document --	1-19															
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>*</sup> Special categories of cited documents:<sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>																	
<b>IV. CERTIFICATION</b> <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none;">Date of the Actual Completion of the International Search</td> <td style="width: 50%; border: none;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="border: 1px solid black; padding: 5px;">14th January 1992</td> <td style="border: 1px solid black; padding: 5px;">1992 -01- 1 5</td> </tr> <tr> <td style="border: none;">International Searching Authority</td> <td style="border: none;">Signature of Authorized Officer</td> </tr> <tr> <td style="border: 1px solid black; padding: 5px; text-align: center;">SWEDISH PATENT OFFICE</td> <td style="border: 1px solid black; padding: 5px; text-align: center;">             Anneli Jönsson         </td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	14th January 1992	1992 -01- 1 5	International Searching Authority	Signature of Authorized Officer	SWEDISH PATENT OFFICE	 Anneli Jönsson							
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report																
14th January 1992	1992 -01- 1 5																
International Searching Authority	Signature of Authorized Officer																
SWEDISH PATENT OFFICE	 Anneli Jönsson																

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
A	Journal of Pharmaceutical Sciences, 75(1986-04):4, N.I. Payne et al: "Characterization of proliposomes" see the entire article --	1-19
A	US, A, 04610868 (MW FOUNTAIN ET AL) 9 September 1986, see the whole document -- -----	1-19

ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO. PCT/SE 91/00639

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the Swedish Patent Office EDP file on 30/11/91  
The Swedish Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0158441	85-10-16	JP-A- 61044808 US-A- 5004611	86-03-04 91-04-02
EP-A- 0260241	88-03-16	AU-B- 603139 AU-D- 7913387 CA-A- 1256798 EP-A- 0282537 JP-T- 1500668 WO-A- 88/01862 ZA-A- 8706641	90-11-08 88-04-07 89-07-04 88-09-21 89-03-09 88-03-24 88-03-14
WO-A1- 8707502	87-12-17	EP-A- 0309464	89-04-05
EP-A- 0084169	83-07-27	NONE	
US-A- 04610868	86-09-09	NONE	

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**